{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:13:06Z","timestamp":1776348786079,"version":"3.51.2"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008990","name":"Zhejiang Province Science and Technology Department","doi-asserted-by":"publisher","award":["2024C03206"],"award-info":[{"award-number":["2024C03206"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012652","name":"Eye Hospital Wenzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ophtha.2025.10.023","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:16:45Z","timestamp":1762190205000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Spleen Tyrosine Kinase and VEGFR-2 Dual-Target Kinase Inhibitor (OT202) in Dry Eye"],"prefix":"10.1016","volume":"133","author":[{"given":"Haiou","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaozhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-2820","authenticated-orcid":false,"given":"Luxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4040-6721","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ophtha.2025.10.023_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2025.10.023_bib2","series-title":"Dry Eye Syndrome. 2024 Feb 29. In: StatPearls [Internet]","author":"Golden","year":"2024"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.023_bib3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/opo.12888","article-title":"The global prevalence of dry eye disease: a Bayesian view","volume":"41","author":"Papas","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.023_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067007","article-title":"Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey","volume":"13","author":"Boboridis","year":"2023","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.023_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1159\/000525696","article-title":"Prevalence and incidence of dry eye disease in Asia: a systematic review and meta-analysis","volume":"65","author":"Cai","year":"2022","journal-title":"Ophthalmic Res"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.023_bib6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1167\/iovs.17-23479","article-title":"Narrow spectrum kinase inhibitors demonstrate promise for the treatment of dry eye disease and other ocular inflammatory disorders","volume":"59","author":"Hagan","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11S","key":"10.1016\/j.ophtha.2025.10.023_bib7","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ophtha.2017.08.029","article-title":"Inflammation in dry eye disease: how do we break the cycle?","volume":"124","author":"Rhee","year":"2017","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.023_bib8","first-page":"71","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Dtsch Arztebl Int"},{"issue":"11s","key":"10.1016\/j.ophtha.2025.10.023_bib9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The pathophysiology of dry eye disease: what we know and future directions for research","volume":"124","author":"Pflugfelder","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.023_bib10","article-title":"Inflammation mechanism and anti-inflammatory therapy of dry eye","volume":"11","author":"Chu","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ophtha.2025.10.023_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/03946320221133018","article-title":"Syk promotes phagocytosis by inducing reactive oxygen species generation and suppressing SOCS1 in macrophage-mediated inflammatory responses","volume":"36","author":"Yi","year":"2022","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.023_bib12","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2023.12.041","article-title":"Dry eye syndrome Preferred Practice Pattern\u00ae","volume":"131","author":"Amescua","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.023_bib13","doi-asserted-by":"crossref","first-page":"106206","DOI":"10.1016\/j.ejps.2022.106206","article-title":"Current trends in pharmaceutical treatment of dry eye disease: a review","volume":"175","author":"Mohamed","year":"2022","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.023_bib14","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/11206721221141481","article-title":"Management of inflammation in dry eye disease: recommendations from a European panel of experts","volume":"33","author":"Messmer","year":"2023","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.023_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/07853890.2022.2157477","article-title":"Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists","volume":"55","author":"Sheppard","year":"2023","journal-title":"Ann Med"},{"issue":"13","key":"10.1016\/j.ophtha.2025.10.023_bib16","article-title":"Reduced central corneal thickness associated with long term treatment with topical steroids","volume":"47","author":"Valavil","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.023_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2019.0060","article-title":"The immunological basis of dry eye disease and current topical treatment options","volume":"36","author":"Periman","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.023_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2025.10.023_bib19","doi-asserted-by":"crossref","first-page":"270302","DOI":"10.1155\/2014\/270302","article-title":"Functional roles of Syk in macrophage-mediated inflammatory responses","volume":"2014","author":"Yi","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"12","key":"10.1016\/j.ophtha.2025.10.023_bib20","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjogren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.023_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/jcmm.12020","article-title":"Novel transcriptional regulation of VEGF in inflammatory processes","volume":"17","author":"Tang","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.023_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234186","article-title":"Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: a double-masked, randomized trial","volume":"15","author":"Kasetsuwan","year":"2020","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.ophtha.2025.10.023_bib23","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2010-09-305284","article-title":"Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase","volume":"117","author":"Kazerounian","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ophtha.2025.10.023_bib24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2010.124","article-title":"Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?","volume":"128","author":"Goyal","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.10.023_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/OPTH.S189039","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease","volume":"13","author":"Taylor","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.023_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.023_bib27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.023_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.023_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2024.0101","article-title":"Water-free cyclosporine ophthalmic solution vs vehicle for dry eye disease: a randomized clinical trial","volume":"142","author":"Peng","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.023_bib30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.023_bib31","first-page":"3043","article-title":"Efficiency and safety of subconjunctival injection of anti-VEGF agent\u2014bevacizumab\u2014in treating dry eye","volume":"9","author":"Jiang","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"10.1016\/j.ophtha.2025.10.023_bib32","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","article-title":"A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients","volume":"96","author":"Takamura","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2025.10.023_bib33","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.023_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study","volume":"252","author":"Sheppard","year":"2023","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025006906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:28:39Z","timestamp":1776346119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025006906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0161642025006906"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.023","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Spleen Tyrosine Kinase and VEGFR-2 Dual-Target Kinase Inhibitor (OT202) in Dry Eye","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}